# Efficacy and Safety of Everolimus in de Novo Kidney Transplant Recipients of ECD or AKI Donors

> **NCT02314312** · PHASE3 · UNKNOWN · sponsor: **Mahidol University** · enrollment: 48 (estimated)

## Conditions studied

- Transplantation of Kidney
- Expanded Criteria Donor
- ECD

## Interventions

- **DRUG:** Everolimus + low dose cyclosporin A + prednisolone
- **DRUG:** Standard immunosupressive regimen

## Key facts

- **NCT ID:** NCT02314312
- **Lead sponsor:** Mahidol University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2014-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02314312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02314312, "Efficacy and Safety of Everolimus in de Novo Kidney Transplant Recipients of ECD or AKI Donors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02314312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*